Literature DB >> 22977564

Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy.

Rie Osaki1, Takashi Nishimura, Takayuki Takeuchi, Hirotsugu Imaeda, Yoshiaki Okumura, Makoto Shioya, Tamio Nakahara, Shigeki Bamba, Shinobu Nakajo, Yoshihide Fujiyama, Akira Andoh.   

Abstract

Prediction of the efficacy of pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy against hepatitis C (HCV) infection is valuable for determining its applications. This study investigated the relationship between the early response of HCV to PEG-IFN/RBV therapy and the inter-leukin (IL)-28B genetic polymorphism in patients with HCV infection. The genotypes of IL-28B rs8099917 T>G single nucleotide polymorphism were determined in 144 patients with HCV infection. Among them, 59 were treated with PEG-IFN/RBV. The frequency of IL-28B TT homozygosity was 75.2% in patients with HCV serotype 1 and 84.6% in patients with serotype 2. Multivariate analysis showed that IL-28B TT homozygosity (P=0.014) and the platelets number (P=0.030) was associated with the early suppression of HCV-RNA at 12 weeks after the start of PEG-IFN/RBV therapy. The IL-28B polymorphism was a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy in patients with HCV infection.

Entities:  

Year:  2011        PMID： 22977564      PMCID： PMC3440742          DOI： 10.3892/etm.2011.250

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN： 1792-0981            Impact factor:   2.447


  18 in total

Review 1.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Differences in epidemiology, liver disease and treatment response among HCV genotypes.

Authors:  Stephanos J. Hadziyannis; John S. Koskinas
Journal:  Hepatol Res       Date:  2004-07       Impact factor: 4.288

Review 3.  Impact of obesity on treatment of chronic hepatitis C.

Authors:  Michael R Charlton; Paul J Pockros; Stephen A Harrison
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

4.  Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases.

Authors:  Seyed-Moayed Alavian; Seyed Vahid Tabatabaei; Maryam Keshvari; Bita Behnava; Seyyed Mohammad Miri; Pegah Karimi Elizee; Kamran Bagheri Lankarani
Journal:  Liver Int       Date:  2010-07-08       Impact factor: 5.828

5.  A randomized clinical trial with natural interferon-alpha monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers.

Authors:  Shiro Iino; Fumihiro Ichida; Akira Sakuma; Hiroshi Suzuki
Journal:  Hepatol Res       Date:  2002-12       Impact factor: 4.288

6.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

7.  Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  Tania Mara Welzel; Timothy R Morgan; Herbert L Bonkovsky; Deepa Naishadham; Ruth M Pfeiffer; Elizabeth C Wright; Amy A Hutchinson; Andrew T Crenshaw; Arman Bashirova; Mary Carrington; Myhanh Dotrang; Richard K Sterling; Karen L Lindsay; Robert J Fontana; William M Lee; Adrian M Di Bisceglie; Marc G Ghany; David R Gretch; Stephen J Chanock; Raymond T Chung; Thomas R O'Brien
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

8.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

9.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.

Authors:  Namiki Izumi; Yasuhiro Asahina; Masayuki Kurosaki
Journal:  Hepat Res Treat       Date:  2010-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.